real life 28 april 2011 10:44 auteur info real life Lid sinds: 06 okt 2008 Laatste bezoek: 18 jul 2022 Aanbevelingen Ontvangen: 13 Gegeven: 77 Aantal posts: 1.280 finance.yahoo.com/news/Cell-Thera...SEATTLE, April 28, 2011 /PRNewswire/ -- Cell Therapeutics, Inc. (Nasdaq and MTA: CTIC) (the "Company") today announced that it has entered into an agreement to sell, subject to customary closing conditions, approximately $16.0 million of shares of its Series 12 Preferred Stock and warrants to purchase shares of its common stock in a registered offering to three institutional investors. Each share of Series 12 Preferred Stock is convertible at the option of the holder, at any time during its existence, into approximately 2,857 shares of common stock at a conversion price of $0.35 per share of common stock, for a total of 45,634,286 shares of common stock.In connection with the offering, the investors received warrants to purchase up to 18,253,714 shares of common stock. The warrants have an exercise price of $0.40 per warrant share, for total potential additional proceeds to the Company of approximately $7.3 million upon exercise of the warrants for cash. The warrants are exercisable immediately and expire five years from the date of issuance. The Company intends to use the net proceeds from the offering for general corporate purposes, which may include, among other things, paying interest on and/or retiring portions of its outstanding debt, funding research and development, preclinical and clinical trials, the preparation and filing of new drug applications and general working capital. The Company may also use a portion of the net proceeds to fund possible investments in, or acquisitions of, complementary businesses, technologies or products. The Company has recently engaged in limited discussions with third parties regarding such investments or acquisitions, but has no current agreements or commitments with respect to any investment or acquisition. Shares of the Series 12 Preferred Stock will receive dividends in the same amount as any dividends declared and paid on shares of common stock and have no voting rights on general corporate matters. The closing of the offering is expected to occur on May 2, 2011, at which time the Company will receive the cash proceeds and deliver the securities. Rodman & Renshaw, LLC, a wholly-owned subsidiary of Rodman & Renshaw Capital Group, Inc., (Nasdaq:RODM - News), acted as the exclusive placement agent for the offering. A shelf registration statement relating to the shares of Series 12 Preferred Stock and warrants issued in the offering (and the shares of common stock issuable upon conversion of the Series 12 Preferred Stock and exercise of the warrants) has been filed with the Securities and Exchange Commission (the "SEC"). A prospectus supplement under Rule 424 of the Securities Act of 1933, as amended, relating to the offering will be filed with the SEC. Copies of the prospectus supplement and accompanying prospectus may be obtained directly from the Company by contacting the Company at the following address: Cell Therapeutics, Inc., 501 Elliott Avenue West, Suite 400, Seattle, Washington 98119. This press release does not constitute an offer to sell or a solicitation of an offer to buy the Series 12 Preferred Stock or warrants (or the shares of common stock issuable upon conversion of the Series 12 Preferred Stock and exercise of the warrants). No offer, solicitation or sale will be made in any jurisdiction in which such offer, solicitation or sale is unlawful. Aanbevelingen 0 ” Quote Reageren Niet oké
welshterrier 5 28 april 2011 14:40 auteur info welshterrier 5 Lid sinds: 23 mrt 2004 Laatste bezoek: 03 mei 2024 Aanbevelingen Ontvangen: 280 Gegeven: 1038 Aantal posts: 20.096 bodemloze put Aanbevelingen 0 ” Quote Reageren Niet oké
welshterrier 5 16 mei 2011 20:42 auteur info welshterrier 5 Lid sinds: 23 mrt 2004 Laatste bezoek: 03 mei 2024 Aanbevelingen Ontvangen: 280 Gegeven: 1038 Aantal posts: 20.096 split vandaag 1 voor 6 aandelen Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 18 mei 2011 17:05 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 quote:welshterrier schreef:split vandaag 1 voor 6 aandelengaat het wel worden ja !! Aanbevelingen 0 ” Quote Reageren Niet oké
welshterrier 5 18 mei 2011 17:27 auteur info welshterrier 5 Lid sinds: 23 mrt 2004 Laatste bezoek: 03 mei 2024 Aanbevelingen Ontvangen: 280 Gegeven: 1038 Aantal posts: 20.096 denk je echt? nu 0,25 oude koers.................. Aanbevelingen 0 ” Quote Reageren Niet oké
welshterrier 5 18 mei 2011 19:28 auteur info welshterrier 5 Lid sinds: 23 mrt 2004 Laatste bezoek: 03 mei 2024 Aanbevelingen Ontvangen: 280 Gegeven: 1038 Aantal posts: 20.096 haha AF 1,81 nu............ Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 20 mei 2011 09:33 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 quote:welshterrier schreef:haha AF 1,81 nu............hoi welsh , het is AG , alleen niet bij EK verkocht op 2.82 en 2 weken later 3.70 !!stom !!ps , ik zie roos niet meer ??? Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 21 mei 2011 09:25 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 quote:welshterrier schreef:haha AF 1,81 nu............2.08 gesloten , 34,5 oude koers !! Aanbevelingen 0 ” Quote Reageren Niet oké
welshterrier 5 23 mei 2011 15:52 auteur info welshterrier 5 Lid sinds: 23 mrt 2004 Laatste bezoek: 03 mei 2024 Aanbevelingen Ontvangen: 280 Gegeven: 1038 Aantal posts: 20.096 quote:ALTIJD - GOED schreef op 21 mei 2011 09:25:[...]2.08 gesloten , 34,5 oude koers !!2,32, zou het toch nog wat worden met CTIC?? Xconomy Network: Select City or Channel ------------- Boston Detroit New York San Diego San Francisco Seattle ------------- National Cleantech Health IT Life Sciences Startups Xconomy NationalAboutContact UsArchivesAdvertiseReprintsE-mail - RSS . SEARCH Seattle HomeLocal EventsBlogrollJobsXconomistsX Lists. ShareTwitter Facebook Email OtherRelated Posts•Cell Therapeutics Sells Remaining Zevalin Stake to Spectrum•Cell Therapeutics Taps Stock Market Again, Seeks $40M or More•Cell Therapeutics Cash To Last Into August•Cell Therapeutics Grabs $15M From Single Investor•Cell Therapeutics Closing Italian Branch, Cutting 62 JobsBiotech, Finances, cancerCell Therapeutics Raises $20M from Single Investor, Hopes to Unload $89.2M in DebtLuke Timmerman 5/11/09 [[Update with corrected Zevalin sale price]] Cell Therapeutics is trying to get rid of a major load of debt. The Seattle biotech company said today it has sold $20 million worth of common stock and warrants to buy stock to a single unnamed institutional investor. It hopes to swap some of that money, along with the $17.8 million in cash it currently has, along with some of its common stock, to wipe out about $89.2 million of its debt that starts coming due as early as next year.The company (NASDAQ: CTIC) has been carrying around more than that, about $120 million of debt, on its balance sheet for years. It borrowed the money back in the days when it had high hopes that its modified form of paclitaxel, a chemotherapy drug, would succeed in clinical trials, and become a big seller. That was supposed to allow the debt to convert into shares, so that the company would never have to pay back the principal. But that drug failed in pivotal clinical trials, driving down Cell Therapeutics stock, and leaving the company on the hook to make debt payments without a blockbuster moneymaking product.Back in February, CEO James Bianco said it would take a “high-wire act” over the next six months to keep the company moving ahead, and that’s apparently what he’s been doing. The company closed down an Italian research center, eliminating more than 60 jobs, sold off its stake in its lone marketed product, ibritumomab tiuxetan (Zevalin) to Spectrum Pharmaceuticals for $31.5 million, and then sold shares to Cranshire Capital for an offering that grossed $23.8 million. All those maneuvers have enabled the company to stretch out its cash reserves to operate into August, to buy some time while it whips up an application to the FDA for another experimental cancer that has sparked high hopes—pixantrone for non-Hodgkin’s lymphoma.Today’s deal is evidently one of several moves the company needs to execute to start building more value from the progress of pixantrone. The drug showed an ability in a clinical trial of 140 patients to completely eliminate tumors in about 20 percent of patients, compared with 5.7 percent who did that well in a control group, although there were more instances of “severe cardiac events” in the group who got pixantrone. Full details will be presented at the American Society of Clinical Oncology meeting in Orlando, FL, later this month, the company has said.While the company assembles its application, the Swiss drug giant Novartis is doing its due diligence on the drug. If Novartis decides to exercise an option to co-market the product, it could pay Cell Therapeutics a $7.5 million fee. That could lead to a total of $40 million in milestone payments in 2009, Bianco said earlier this year in an investor presentation. Novartis could pay the bills for commercializing the product, and leave Cell Therapeutics with a double-digit percentage royalty on sales, he said.Cell Therapeutics said it currently has about $118.9 million in debt outstanding, and that it hopes to exchange cash to get rid of $89.2 million in the near future. The company expects to offer investors cash and stock in the range of $250 to $300 for every $1,000 increment of debt securities they hold.“The company believes that reducing its outstanding indebtedness is necessary in order for its business to operate in light of the current asset base and revenue projections,” the company said in a statement Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 23 mei 2011 15:59 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 quote:welshterrier schreef:[quote alias=ALTIJD - GOED id=5583717 date=201105210925][...]2.08 gesloten , 34,5 oude koers !![/quote]2,32, zou het toch nog wat worden met CTIC??denk het niet , push en dump Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 23 mei 2011 16:07 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 maar je weet mijn reputatie, ik wilde vorige week ernog wat oppikken en zag 1.47 staan en durfde niet ,nu maar wel gedaan Aanbevelingen 0 ” Quote Reageren Niet oké
welshterrier 5 23 mei 2011 16:18 auteur info welshterrier 5 Lid sinds: 23 mrt 2004 Laatste bezoek: 03 mei 2024 Aanbevelingen Ontvangen: 280 Gegeven: 1038 Aantal posts: 20.096 Maar of er ooit een goedkeuring komt.... Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 26 januari 2012 16:38 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 Cell Therapeutics, Inc. (CTIC) $1.37 Up 0.02(1.48%) Komt weldra weer volop in de picture met de volgende 2 gebeurtenissen op Do 9 Februari en Di 24 April1) Cell Therapeutics, Inc. (CTIC)Cell Therapeutics is a biopharmaceutical company engaged in the development, acquisition, and commercialization of drugs for the treatment of cancer.On February 9, the company is expected to receive insights from a FDA panel to review PIXUVRI for treatment of relapsed or refractory Non-Hodgkin's Lymphoma. This is a New Drug Application resubmission.The stock has traded well in recent weeks, and closed January 24, at $1.40. I may establish a $1.50 calendar call spread if volume is present and the stock continues to act in an upward trajecotry. 2) CTIC: FDA DecisionCell Therapeutics, Inc. ("CTI") (NASDAQ and MTA: CTIC) announced that the U.S. Food and Drug Administration's ("FDA") Division of Oncology Products 1 ("DOP1") has notified CTI that CTI's October 2011 resubmitted New Drug Application ("NDA") is considered a complete, Class 2 response to the FDA's April 2010 complete response letter ("CRL").The FDA has set a Prescription Drug User Fee Act ("PDUFA") goal date of April 24, 2012 for a decision on the NDA. The NDA seeks accelerated approval of pixantrone to treat relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL") in patients who failed two or more lines of prior therapy.Pixantrone is also under review for marketing approval in Europe with a Committee for Human Medicinal Products ("CHMP") opinion on the application tentatively scheduled on January 19, 2012.James A. Bianco, M.D. Chief Executive Officer stated that the company looks forward to working with the FDA and the European Medicines Agency ("EMA") to bring this drug to patients for whom there are currently no approved therapies.CTI appealed the CRL for the pixantrone NDA based on the results of the PIX301 clinical trial.The FDA's Office of New Drugs ("OND") responded to CTI's appeal by providing CTI with an opportunity to resubmit the NDA with additional information, but without conducting an additional clinical trial.In June 2011, CTI met with the DOP1 to review CTI's plans for responding to the items noted in the CRL including CTI's plans for addressing the items noted by the OND in response to the appeal.Skip Aanbevelingen 0 ” Quote Reageren Niet oké
welshterrier 5 27 januari 2012 10:48 auteur info welshterrier 5 Lid sinds: 23 mrt 2004 Laatste bezoek: 03 mei 2024 Aanbevelingen Ontvangen: 280 Gegeven: 1038 Aantal posts: 20.096 ik blijf er lekker vanaf Aanbevelingen 0 ” Quote Reageren Niet oké
[verwijderd] 30 januari 2012 17:29 auteur info [verwijderd] Lid sinds: 01 jan 0001 Laatste bezoek: 01 jan 0001 Aanbevelingen Ontvangen: 0 Gegeven: 0 Aantal posts: 0 quote:welshterrier schreef op 27 januari 2012 10:48:ik blijf er lekker vanafEn nog groot gelijk ook na wat ze vandaag te vertellen hadden.More Drama From Cell Therapeutics.Very early on Monday morning, Cell Therapeutics, Inc. (NASDAQ:CTIC) told Wall Street that they need additional time to prepare for the highly anticipated review of the Pixuvri NDA by the FDA's Oncologic Drugs Advisory Committee ("ODAC") at its February 9, 2012 meeting.In a press release, the firm announced that it has voluntarily withdrawn its New Drug Application ("NDA") for Pixuvri (pixantrone) for the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma ("NHL") in patients who failed two or more lines of prior therapy.CTIC shares had just seen its shares jump 15% two Fridays ago following news that Pixuvri should receive a decision on its marketability by the European Medicine Agency by mid-February. Now this.Is it any wonder CTIC shares can't seem to break out of the painfully slow down-ward trend they've been on for years?Officials at the company say that drug application was withdrawn because after communications with the FDA, Cell Therapeutics managment decided they needed additional time to prepare for the review of the Pixuvri NDA by the FDA's Oncologic Drugs Advisory Committee at its February 9, 2012 meeting.According to officials, prior to withdrawing the NDA, the company had requested that the FDA consider rescheduling the review - even suggesting that the review be pushed back until March - but regulators informed the company that they were unable to accommodate the request to reschedule, and that given the April 24, 2012 Prescription Drug User Fee Act ("PDUFA") date, the only way to have Pixuvri possibly considered at a later ODAC meeting was for CTI to withdraw and later resubmit the NDA.For now, it appears CTI plans to resubmit the NDA sometime in 2012. At what point the clock starts again remains to be seen.In the past, Cell Therapeutics failed to meet its own clinical trial guidelines but was able to get regulators to agree that they would resubmit their study without running new studies. At the very least, biotech traders were looking forward to the February meeting as a run-up catalyst.Very few of those traders it seems would consider taking any sort of stake in the company as investors given that the company has run up a bill totalling $1.7 billion since it was founded and they have no marketable drugs. Bashers say that the company is notorious for diluting shareholder value by raising money on a regular basis and that there are far more intriguing biotech plays - many with multiple shots on goal - which should be taken more seriously as investment candidates.A little more background: Pixantrone is a topoisomerase II inhibitor, which is similar in structure to a class of molecules known as anthracyclines. These molecules all serve as effective therapeutics for the treatment of lymphoma although they induce cardiovascular damage. Due to this, patients cannot use anthracyclines past a certain threshold.According to Cell Therapeutics, Pixantrone is a substantial improvement since it causes less damage to the patient's vascular system. A patient on Pixantrone can be injected through a peripheral vein, and will not need a catheter. In addition, Cell's PIX301 clinical trial of Pixantrone has confirmed statistically significant results regarding the drug's efficacy. After months of discussing an NDA resubmission with the FDA after its initial rejection, Cell believed that it had addressed all the issues brought up in the initial filing.When the firm resubmitted the Pixantrone NDA to the FDA for consideration of accelerated approval they seemed rather optimistic; James A. Bianco, M.D., CEO, said: We believe the resubmitted NDA not only addresses the items in the Complete Response Letter, but confirms the reliability of the initial efficacy results, which we believe demonstrates that pixantrone does provide a clinical benefit to this patient population for which there are no currently approved therapies.Now, once again CTIC shareholders are left feeling frustrated . Unlike other firms who drop big news on investors in the middle of the night, CTIC did not give any indication that they would be holding a conference call to explain anything in any detail to anyone.The power for life support that this one is on may have just dimmed. Still, the CTIC hopefuls will likely hold on to hope and whatever value their shares may hold by the end of the trading day.Skip Aanbevelingen 0 ” Quote Reageren Niet oké
Beurscodes, betekenis en hulp bij zoeken Europa AEX Euronext Amsterdam BRU Euronext Brussels PSE Euronext Paris LIS Euronext Lissabon CHX CBOE Europe, grote(re) EU aandelen NAV Investment Funds (NAV) Noord-Amerika NYS New York Stock Exchange OTC CBOE BZX Exchange (US) TSE Toronto Stock Exchange Kunt u een instrument niet vinden? Zoek dan via de zogenaamde ISIN code. Elk instrument, aandeel etc. heeft een unieke code. Kies vervolgens - wanneer er meerdere resultaten zijn - de notering op de beurs van uw keuze. Waar vind ik die ISIN code? Google de naam van het instrument, aandeel etc. met de toevoeging 'ISIN'. Als zoeken op ISIN code geen resultaten oplevert hebben wij het instrument of aandeel niet in onze koersendatabase.